Turn Therapeutics Inc. (TTRX) Financial Statements
Free cash flow over the same period: -$4.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TTRXTurn Therapeutics Inc.Follow TTRX — free
—
Price chart with a free account
- Market cap
- 306.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 0.2 | 0.3 | 0.8 | |
| Operating income | -1.8 | -5.9 | -7.0 | |
| Pre-tax income | -1.8 | -3.2 | -8.4 | |
| Net income | -1.8 | -3.2 | -8.4 | |
| Diluted EPS ($) | -0.07 | -0.12 | -0.29 | |
| Diluted shares (mn) | 26.6 | 27.7 | — |
USD millions · SEC XBRL
Turn Therapeutics Inc. — questions
- What is Turn Therapeutics Inc.'s net income?
- -$8.4M over the twelve months to 2026-06-30.
- What is Turn Therapeutics Inc.'s free cash flow?
- -$4.3M over the twelve months to 2026-06-30.
- What are Turn Therapeutics Inc.'s diluted earnings per share?
- $-0.29 over the twelve months to 2026-06-30.
Every figure on this page comes from Turn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.